Get the latest news, insights, and market updates on HALO (Halozyme Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Why Halozyme Therapeutics (HALO) Is Down 7.9% After Acquisition-Driven Q4 Loss And 2026 Outlook Reaffirmation
In February 2026, Halozyme Therapeutics reported Q4 2025 revenue of US$451.77 million and full‑year revenue of US$1.40 billion, but a quarterly net loss of US$141.59 million driven by acquisition-related impairment and IPR&D charges, while reiterating 2026 revenue guidance of US$1.71 billion to US$1.81 billion. Alongside strong ENHANZE-driven revenue momentum and recent deals for new hyperconcentration drug delivery technologies, management signaled plans to keep using robust cash flow for... Feb 19, 2026 - $HALO
Halozyme (HALO) Loses 9% on Weak Earnings
We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday. Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent to finish at $73.23 as investors digested a weak earnings performance in both the fourth quarter and full-year 2025. In an […] Feb 19, 2026 - $HALO
Halozyme Therapeutics Q4 Earnings Call Highlights
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a “significant and value-creating” 2025, pointing to accelerating royalty growth from ENHANZE-enabled products, expansion into additional subcutaneous drug delivery technologies through acquisitions, and a widening pip Feb 18, 2026 - $HALO
Russell Investments Expands Canadian ETF Lineup With Five New Offerings
TORONTO, February 18, 2026--Russell Investments Canada Limited today announced the launch of five new exchange-traded funds (ETFs) on the Toronto Stock Exchange (TSX), further expanding its Canadian ETF platform and giving investors additional cost-effective options across core fixed income and equity allocations. Feb 18, 2026 - $HALO
Is Halozyme Therapeutics (HALO) Stock Price Out Of Step With Recent Valuation Signals
If you are looking at Halozyme Therapeutics and wondering whether the current share price lines up with its underlying value, this article will walk through the key numbers so you can judge that for yourself. The stock recently closed at US$80.48, with returns of 0.3% over the past week, 13.0% over 30 days, 14.5% year to date, 39.0% over 1 year, 62.1% over 3 years and 70.5% over 5 years, which may have changed how some investors view its potential and risk profile. Recent coverage around... Feb 18, 2026 - $HALO
Halozyme (HALO) Q4 2025 Earnings Call Transcript
As I look back on the past year, it is clear that 2025 was one of the most significant and value-creating years in Halozyme Therapeutics, Inc.'s history. This level of execution has created a clear value inflection for Halozyme Therapeutics, Inc., unlocking multiple drivers of long-term, durable, and profitable revenue. Chris will be reviewing the new potential opportunity that is emerging on the uses of ENHANZE with antibody-drug conjugates. Feb 17, 2026 - $HALO
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. Feb 17, 2026 - $HALO
Halozyme Therapeutics: Q4 Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of $1.20. Losses, adjusted for one-time gains and costs, were 24 cents per share. The results missed Wall Street expectations. Feb 17, 2026 - $HALO
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple